Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Alzheimer's Disease (AD)
Interventions: ABBV-916, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 32
States / cities: Tucson, Arizona • Irvine, California • San Diego, California + 23 more

Conditions: Healthy Volunteers
Interventions: TAK-648 Tablet, TAK-648 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: TRV734; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 46
States / cities: Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more

Conditions: Breast Cancer
Interventions: Gemcitabine, Sorafenib, Placebo, Capecitabine; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 44
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more

Conditions: Contraception
Interventions: Norgestrel 0.075 mg; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Sacramento, California • Portland, Oregon

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Autism Spectrum Disorder
Interventions: Balovaptan, Esomeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PS-341, Doxil, Velcade; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: LY3337641, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Palm Desert, California • Palo Alto, California • Denver, Colorado + 12 more

Conditions: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Interventions: Triheptanoin; Drug
Lead sponsor: Adrian Lacy; Other
Eligibility: 1 Year to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Corneal Edema After Cataract Surgery
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more

Conditions: Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Healthy Participants
Interventions: Vonoprazan, Lansoprazole; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Lenvatinib 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Colorectal Cancer
Interventions: celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 826
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more

Conditions: Lung Cancer, Adenocarcinoma
Interventions: Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: COVID, Infectious Disease
Interventions: High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP); Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 12 Months and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 80
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more

Conditions: Healthy
Interventions: 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo; Combination Product · Drug · Other
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Asthma, Allergic Rhinitis
Interventions: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 6 Years to 15 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Green Tree, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Active Non-segmental Vitiligo
Interventions: PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 40
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more

Search by objective public record fields.

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

A Study of LY3337641 in Rheumatoid Arthritis

An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Staccato® Granisetron Single Dose PK

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects